NL and BC contributed equally to this Correspondence. The Sepsis James Lind Alliance Priority Setting partnership was funded by Sepsis Research (FEAT). All authors are part of the Sepsis James Lind Alliance Priority Setting Partnership steering group and attended the final workshop, which was funded by Sepsis Research (FEAT). JM has received consultancy fees, paid to their institution, from AstraZeneca, lecture honoraria from Yale University, and research funding from Sepsis Research (FEAT) and The Healthcare Improvement Studies Institute (University of Cambridge). JM, BC, and NL all receive funding from the National Institute for Health and Social Care Research (NIHR) UK. NL receives research funding from the Chief Scientist Office, is Chair of the Scottish Intensive Care Society Audit Group, Public Health Scotland, and is Director of Research for the Intensive Care Society (UK). BC is Director of Research for the Intensive Care Society (UK), Chair of the UK Critical Care Research Group, and is Deputy Chair of the NIHR National Speciality Critical Care Group. CG is the Chief Operating Officer for Sepsis Research (FEAT) and is paid by the charity. NA has received consultancy fees for her role as James Lind Alliance adviser for the project. MO is a patient partner and declares no competing interests.